FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMP Number:	2225.0

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  AGARWAL SUNIL						2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [ RARE ]								(Che	ck all applic Directo	cable) r	10% Owner		
(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT						3. Date of Earliest Transaction (Month/Day/Year) 08/19/2015									X Officer (give title Other (spe below) below)  Chief Medical Officer				
(Street) NOVATO	) C.	A	_   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									lividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				1		
(City)	(S		(Zip)	Non Don				A			Nia	-6	D	: -: - !!.	. O				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye.					on	2A. Deemed Execution Date,		ate,	3. Transa	4. Securities Ad Of (D) (Instr. 3,		Acquired (A) or Dis			5. Amou Securiti Benefici Owned	int of es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	ct c	7. Nature of Indirect Beneficial Ownership
			Ī	Code	v			Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)			
Common Stock			08/19/20	)15	.5			F		5,480(1)	D	\$11	\$116.99		920 <sup>(2)</sup>	D			
Common Stock			08/20/20	015				<b>S</b> <sup>(3)</sup>		3,370	D	\$112	\$112.1892 <sup>(4)</sup>		550 <sup>(2)</sup>	D			
Common Stock			08/20/20	)15				S <sup>(3)</sup>		3,650	D	\$112.7284 <sup>(5)</sup>		16,	900 <sup>(2)</sup>	D			
Common Stock			08/20/20	015	15			M		10,000	A	\$55.88		26,	900 <sup>(2)</sup>	D			
Common Stock 0			08/20/20	)15	15					724	D	\$107.302 <sup>(6)</sup>		26,	176 <sup>(2)</sup>	D			
Common Stock 08/20/				08/20/20	015	15					1,471	D	\$108.9801 <sup>(7)</sup>		24,	24,705 <sup>(2)</sup>			
Common Stock 08/20/2				08/20/20	)15	5		S			4,875	D	\$110.3961(8)		19,	19,830 <sup>(2)</sup>			
Common Stock 08/20/201					015	5			S <sup>(3)</sup>		2,000	D	\$111.214 <sup>(9)</sup>		17,	17,830 <sup>(2)</sup>			
Common Stock			08/20/20	)15				S <sup>(3)</sup>		930	D	\$111.9035(10)		16,900 <sup>(2)</sup>		D			
		-	Table								sposed of				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any		4. Trans Code 8)	action	5. Number of		6. Date Ex Expiration (Month/Da		rcisable and Date	7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		nount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct ( or Indir (I) (Inst	(D) irect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	e rcisable	Expiration Date	Title	or Nu of	nount mber ares					
Stock Option (Right to Buy)	\$55.88	08/20/2015			М			10,000		(11)	08/18/2024	Comm		,000	\$0.00	.00 140,000		D	

## **Explanation of Responses:**

- 1. Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due upon vesting of Restricted Stock Units granted to the Reporting Person under the Issuers 2014 Incentive Plan. The shares surrendered were valued based on the closing price of the Issuers common stock on the vesting date.
- 2. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- 3. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.9100 to \$112.4500 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$112.4600 to \$113.3800 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the
- 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$107.1103 to \$107.5100 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$108.6900 to \$109.6700 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$109.7367 to \$110.6900 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the
- 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.7600 to \$111.7000 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the

range.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.8800 to \$111.9100 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

11. 1/4th of the shares underlying the option vested on August 19, 2015, and then 1/48th of the underlying shares will vest monthly thereafter, provided the Reporting Person has not terminated services with the Issuer

## Remarks:

<u>/s/ Sunil Agarwal</u> <u>08/21/2015</u>

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.